Seroepidemiology of Human Bocavirus Defined Using Recombinant Virus-Like Particles
Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera an...
Saved in:
| Published in | The Journal of Infectious Diseases Vol. 198; no. 1; pp. 41 - 50 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chicago, IL
The University Chicago Press
01.07.2008
University of Chicago Press |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulinGantibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale–New Haven Hospital; 208 specimens were also screened for erythrovirus B19–specific antibodies by a B19 VLP–based ELISA. Results. Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP–based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%–60.0% for children 5l–47 months of age and to >85% for individuals ⩾48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. Conclusions. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. |
|---|---|
| AbstractList | Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-speciflc antibodies by a B19 VLP-based ELISA. Results. Immunofluorescence and ELISA showed that human parvo viruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals ≥ 48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. Conclusions. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antlgenlc properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific Immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA. Results. Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seroposittve, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals less than or equal to 48 months old. However, the overall percentage of B19-seropositlve individuals was <40.5% for all age groups screened. Conclusions. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA. Results. Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seroposittve, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals less than or equal to 48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. Conclusions. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined.BACKGROUNDHuman bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined.The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA.METHODSThe HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA.Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals >or=48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened.RESULTSImmunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals >or=48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened.HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection.CONCLUSIONSHBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Background . Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods . The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulinGantibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA. Results . Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5l-47 months of age and to >85% for individuals ⩾48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. Conclusions . HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulin G antibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale-New Haven Hospital; 208 specimens were also screened for erythrovirus B19-specific antibodies by a B19 VLP-based ELISA. Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP-based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%-60.0% for children 5-47 months of age and to >85% for individuals >or=48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The HBoV VP2 gene, expressed from a baculovirus vector, produced virus-like particles (VLPs), which were used to raise rabbit anti-HBoV antisera and to develop an enzyme-linked immunosorbent assay (ELISA). The VLP-based ELISA was used to screen for HBoV-specific immunoglobulinGantibodies in a convenience sample of 270 serum specimens, mostly from children, obtained at Yale–New Haven Hospital; 208 specimens were also screened for erythrovirus B19–specific antibodies by a B19 VLP–based ELISA. Results. Immunofluorescence and ELISA showed that human parvoviruses HBoV and B19 are antigenically distinct. By the HBoV VLP–based ELISA, 91.8% and 63.6% of serum specimens from infants in the first and second months of life, respectively, were found to be seropositive, as were 45.4% from 3-month-old infants and 25.0% from 4-month-old infants. The percentages of HBoV-seropositive children increased to 40.7%–60.0% for children 5l–47 months of age and to >85% for individuals ⩾48 months old. However, the overall percentage of B19-seropositive individuals was <40.5% for all age groups screened. Conclusions. HBoV infection is common during childhood, but a minority of children and young adults screened have evidence of B19 infection. |
| Author | Kahn, Jeffrey S. Weibel, Carla Kesebir, Deniz Cotmore, Susan F. D'Abramo, Anthony Tattersall, Peter Cosby, Christi |
| Author_xml | – sequence: 1 givenname: Jeffrey S. surname: Kahn fullname: Kahn, Jeffrey S. email: jeffrey.kahn@yale.edu organization: Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut – sequence: 2 givenname: Deniz surname: Kesebir fullname: Kesebir, Deniz organization: Division of Respiratory Medicine, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut – sequence: 3 givenname: Susan F. surname: Cotmore fullname: Cotmore, Susan F. organization: Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut – sequence: 4 givenname: Anthony surname: D'Abramo fullname: D'Abramo, Anthony organization: Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut – sequence: 5 givenname: Christi surname: Cosby fullname: Cosby, Christi organization: Departments of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut – sequence: 6 givenname: Carla surname: Weibel fullname: Weibel, Carla organization: Division of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut – sequence: 7 givenname: Peter surname: Tattersall fullname: Tattersall, Peter organization: Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20427162$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18491974$$D View this record in MEDLINE/PubMed |
| BookMark | eNqN0U1v1DAQBmALFdHtAv8AFA5wIuBvx0co0EVaCdTSgrhYju1UbhN7sR1E_z2psgQJCcHJh_eZ8WjmCByEGBwADxF8gWDDX7Km4YLeASvEiKg5k-gArCDEuEaNlIfgKOcrCBFqILsHDlFDJZKCrsDpmUvR7bx1g499vLypYldtxkGH6nU0-rtPY67euM4HZ6vz7MNldepMHFofdCjVxW1eb_21qz7qVLzpXb4P7na6z-7B_l2D83dvPx1v6u2Hk_fHr7a1oY0oNbOYWSKJ7AgWDELKLG81oZQjK0nbNlZKDDm3FElmWykglaIVmGLiaDuVrsGzue8uxW-jy0UNPhvX9zq4OGYlEOcYEvFPOG2CYSLp_0Aq6dRzDR7v4dgOzqpd8oNON-rXXifwdA90Nrrvkg7G58VhSPE0Hp7c89mZFHNOrlPGF118DCVp3ysE1e151Xze3wMufPn5T_hkhnHc_d08ms1VLjEtikLMyLT6Ka_n3Ofifiy5TteKCyKY2nz5qk4YlOzs4rMS5CdgiMLR |
| CODEN | JIDIAQ |
| CitedBy_id | crossref_primary_10_1016_j_jcv_2009_04_005 crossref_primary_10_3201_eid1507_090102 crossref_primary_10_1016_j_meegid_2011_01_016 crossref_primary_10_1093_infdis_jiv044 crossref_primary_10_1186_s12879_018_3225_3 crossref_primary_10_3390_v7030996 crossref_primary_10_1128_JVI_02569_08 crossref_primary_10_1111_j_1651_2227_2010_01924_x crossref_primary_10_1097_INF_0b013e3182932f4f crossref_primary_10_1146_annurev_virology_092818_015803 crossref_primary_10_1128_JCM_01508_09 crossref_primary_10_1371_journal_pone_0039644 crossref_primary_10_3201_eid1508_090270 crossref_primary_10_1007_s00705_014_2238_5 crossref_primary_10_1016_j_cll_2009_07_010 crossref_primary_10_2217_fvl_11_136 crossref_primary_10_3390_microorganisms11051243 crossref_primary_10_1111_imm_12202 crossref_primary_10_3748_wjg_v22_i39_8684 crossref_primary_10_1016_j_cll_2014_02_011 crossref_primary_10_1002_ppul_21151 crossref_primary_10_1007_s00253_016_7336_8 crossref_primary_10_3201_eid1802_111293 crossref_primary_10_1371_journal_pone_0034353 crossref_primary_10_1155_2021_7035081 crossref_primary_10_1016_j_nmni_2016_01_015 crossref_primary_10_1128_JCM_01157_13 crossref_primary_10_1128_CMR_00040_16 crossref_primary_10_1097_MCP_0b013e328351f8d4 crossref_primary_10_1637_10371_091212_ResNote_1 crossref_primary_10_1111_j_1365_3083_2010_02483_x crossref_primary_10_2478_prolas_2019_0021 crossref_primary_10_1016_j_jcv_2010_02_003 crossref_primary_10_1016_j_jviromet_2014_06_007 crossref_primary_10_1007_s13546_012_0634_y crossref_primary_10_1038_srep39267 crossref_primary_10_1016_j_jcv_2009_11_015 crossref_primary_10_1007_s00112_010_2302_5 crossref_primary_10_1371_journal_pone_0038206 crossref_primary_10_1128_CVI_00355_09 crossref_primary_10_1007_s12519_010_0009_2 crossref_primary_10_1097_INF_0b013e3181f12fcf crossref_primary_10_3390_v1010003 crossref_primary_10_1128_CVI_00470_08 crossref_primary_10_3201_eid1509_090204 crossref_primary_10_1038_s41467_022_32406_w crossref_primary_10_1186_1471_2334_10_215 crossref_primary_10_1128_JVI_02998_15 crossref_primary_10_1111_j_1469_0691_2011_03756_x crossref_primary_10_1371_journal_pone_0086960 crossref_primary_10_1371_journal_pone_0122751 crossref_primary_10_1007_s00705_019_04368_w crossref_primary_10_1007_s00705_012_1407_7 crossref_primary_10_1007_s10096_014_2215_7 crossref_primary_10_1016_S1413_8670_12_70272_6 crossref_primary_10_1002_rmv_648 crossref_primary_10_1128_AEM_00456_21 crossref_primary_10_1002_rmv_720 crossref_primary_10_1111_apa_12502 crossref_primary_10_1097_MRM_0b013e328331ad4a crossref_primary_10_1097_INF_0b013e31827fef67 crossref_primary_10_1128_JVI_00614_09 crossref_primary_10_1016_j_jcv_2008_08_009 crossref_primary_10_1186_1743_422X_8_62 crossref_primary_10_1128_JVI_01770_13 crossref_primary_10_1128_JCM_00196_10 crossref_primary_10_1128_JVI_02719_09 crossref_primary_10_1002_jmv_23880 crossref_primary_10_1016_j_jcv_2015_09_008 crossref_primary_10_2217_fvl_11_78 crossref_primary_10_2478_prolas_2019_0046 |
| Cites_doi | 10.3201/eid1209.051616 10.1086/521311 10.1017/S0022172400060964 10.1086/512163 10.3201/eid1708.060213. 10.1002/jmv.20815 10.1086/368382 10.1086/512196 10.1002/jmv.20689 10.1086/521366 10.1128/JVI.68.7.4690-4694.1994 10.1086/521310 10.1016/S0022-3476(81)80829-3 10.1128/JCM.01044-06 10.3201/eid1205.051424 10.3201/eid1304.061501 10.1186/1750-9378-2-3 10.1128/JCM.44.3.1132-1134.2006 10.1017/S0950268899003817 10.1073/pnas.0402992101 10.1086/508219 10.1016/S0140-6736(04)17398-4 10.1128/JCM.02140-06 10.1073/pnas.0504666102 10.1128/JVI.00815-07 10.3201/eid1209.060417 10.1016/0166-0934(92)90098-X 10.1128/JCM.01884-06 10.1093/infdis/172.6.1431 10.1128/JCM.43.3.1213-1219.2005 10.1182/blood-2003-01-0069 10.1086/508213 10.1128/JVI.60.2.548-557.1986 |
| ContentType | Journal Article |
| Copyright | Copyright 2008 Infectious Diseases Society of America 2008 by the Infectious Diseases Society of America. 2008 2008 INIST-CNRS |
| Copyright_xml | – notice: Copyright 2008 Infectious Diseases Society of America – notice: 2008 by the Infectious Diseases Society of America. 2008 – notice: 2008 INIST-CNRS |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
| DOI | 10.1086/588674 |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1537-6591 1537-6613 |
| EndPage | 50 |
| ExternalDocumentID | 18491974 20427162 10_1086_588674 10.1086/588674 40253992 ark_67375_HXZ_G5095SVW_7 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NICHD NIH HHS grantid: T32HD 07094 – fundername: NIAID NIH HHS grantid: AI 072166 – fundername: NIAID NIH HHS grantid: R21 AI072166 |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- -DZ -~X .XZ 123 29K 70D 85S AAHBH AAHTB AAPNW AAWTL AAYOK ABKDP ABNKS ABPEJ ABPPZ ABZBJ ACGOD ADEYI ADOCK AFYAG AGKEF AIJHB BR6 D-I ECGQY GX1 IH2 KQ8 LSO LU7 W2D WH7 AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 .55 .GJ 1KJ 3O- 41~ AAFWJ AAPGJ AAWDT AAYXX ABDPE ABSMQ ACFRR ACPQN ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AVNTJ BZKNY CITATION EIHJH J5H MBLQV MVM NEJ OBFPC O~Y P0- VH1 X7M Y6R ZE2 ZGI ZXP IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
| ID | FETCH-LOGICAL-c487t-5d25d3939f32750045d6ba34461d93bb8d992066d4195db970497b72423e4b5d3 |
| ISSN | 0022-1899 |
| IngestDate | Fri Jul 11 00:32:22 EDT 2025 Tue Aug 05 10:28:11 EDT 2025 Tue Aug 05 11:19:24 EDT 2025 Thu Apr 03 07:07:57 EDT 2025 Mon Jul 21 09:13:47 EDT 2025 Tue Jul 01 03:24:01 EDT 2025 Thu Apr 24 22:52:48 EDT 2025 Wed Sep 11 04:50:41 EDT 2024 Fri Jun 20 02:32:01 EDT 2025 Tue Aug 05 16:50:06 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Infection Microbiology Recombinant virus Virus like particle Serology Human bocavirus Epidemiology |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c487t-5d25d3939f32750045d6ba34461d93bb8d992066d4195db970497b72423e4b5d3 |
| Notes | istex:14AB5EEFFCE769E2B121E7BDE97A259CADC161B4 ark:/67375/HXZ-G5095SVW-7 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/jid/article-pdf/198/1/41/18053311/198-1-41.pdf |
| PMID | 18491974 |
| PQID | 19749420 |
| PQPubID | 23462 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_71662037 proquest_miscellaneous_19752394 proquest_miscellaneous_19749420 pubmed_primary_18491974 pascalfrancis_primary_20427162 crossref_citationtrail_10_1086_588674 crossref_primary_10_1086_588674 oup_primary_10_1086_588674 jstor_primary_40253992 istex_primary_ark_67375_HXZ_G5095SVW_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-07-01 |
| PublicationDateYYYYMMDD | 2008-07-01 |
| PublicationDate_xml | – month: 07 year: 2008 text: 2008-07-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Chicago, IL |
| PublicationPlace_xml | – name: Chicago, IL – name: United States |
| PublicationTitle | The Journal of Infectious Diseases |
| PublicationTitleAbbrev | The Journal of Infectious Diseases |
| PublicationTitleAlternate | The Journal of Infectious Diseases |
| PublicationYear | 2008 |
| Publisher | The University Chicago Press University of Chicago Press |
| Publisher_xml | – name: The University Chicago Press – name: University of Chicago Press |
| References | rf19_310 rf3_294 rf8_299 rf28_319 rf12_303 Anderson MJ (rf33_324) 1984; 93 Cotmore SF (rf23_314) 1986; 60 rf2_293 rf22_313 rf29_320 rf35_326 Kaplan NM (rf7_298) 2006; 12 rf24_315 rf13_304 rf16_307 Vicente D (rf17_308) 2007; 13 rf9_300 Soderlund M (rf27_318) 1995; 172 rf34_325 rf31_322 rf20_311 rf10_301 rf15_306 Wong S (rf25_316) 1994; 68 Parker JC (rf32_323) 1970; 45 Smuts H (rf11_302) 2006; 12 rf6_297 rf26_317 Bastien N (rf4_295) 2006; 12 Glezen WP (rf30_321) 1981; 98 rf14_305 rf18_309 rf1_292 rf21_312 Foulongne V (rf5_296) 2006; 12 |
| References_xml | – volume: 12 start-page: 1457 year: 2006 ident: rf11_302 publication-title: South Africa. Emerg Infect Dis doi: 10.3201/eid1209.051616 – ident: rf20_311 doi: 10.1086/521311 – volume: 93 start-page: 85 year: 1984 ident: rf33_324 publication-title: J Hyg (Lond) doi: 10.1017/S0022172400060964 – ident: rf6_297 doi: 10.1086/512163 – volume: 12 start-page: 1251 year: 2006 ident: rf5_296 publication-title: Emerg Infect Dis doi: 10.3201/eid1708.060213. – ident: rf12_303 doi: 10.1002/jmv.20815 – ident: rf28_319 doi: 10.1086/368382 – ident: rf16_307 doi: 10.1086/512196 – ident: rf3_294 doi: 10.1002/jmv.20689 – ident: rf19_310 doi: 10.1086/521366 – volume: 68 start-page: 4690 year: 1994 ident: rf25_316 publication-title: J Virol doi: 10.1128/JVI.68.7.4690-4694.1994 – ident: rf18_309 doi: 10.1086/521310 – volume: 98 start-page: 708 year: 1981 ident: rf30_321 publication-title: J Pediatr doi: 10.1016/S0022-3476(81)80829-3 – ident: rf13_304 doi: 10.1128/JCM.01044-06 – volume: 45 start-page: 305 year: 1970 ident: rf32_323 publication-title: J Natl Cancer Inst – ident: rf2_293 – volume: 12 start-page: 848 year: 2006 ident: rf4_295 publication-title: Canada. Emerg Infect Dis doi: 10.3201/eid1205.051424 – volume: 13 start-page: 636 year: 2007 ident: rf17_308 publication-title: Emerg Infect Dis doi: 10.3201/eid1304.061501 – ident: rf9_300 doi: 10.1186/1750-9378-2-3 – ident: rf10_301 doi: 10.1128/JCM.44.3.1132-1134.2006 – ident: rf34_325 doi: 10.1017/S0950268899003817 – ident: rf22_313 doi: 10.1073/pnas.0402992101 – ident: rf15_306 doi: 10.1086/508219 – ident: rf29_320 doi: 10.1016/S0140-6736(04)17398-4 – ident: rf21_312 doi: 10.1128/JCM.02140-06 – ident: rf1_292 doi: 10.1073/pnas.0504666102 – ident: rf26_317 doi: 10.1128/JVI.00815-07 – volume: 12 start-page: 1418 year: 2006 ident: rf7_298 publication-title: Jordan. Emerg Infect Dis doi: 10.3201/eid1209.060417 – ident: rf24_315 doi: 10.1016/0166-0934(92)90098-X – ident: rf14_305 doi: 10.1128/JCM.01884-06 – volume: 172 start-page: 1431 year: 1995 ident: rf27_318 publication-title: J Infect Dis doi: 10.1093/infdis/172.6.1431 – ident: rf31_322 doi: 10.1128/JCM.43.3.1213-1219.2005 – ident: rf35_326 doi: 10.1182/blood-2003-01-0069 – ident: rf8_299 doi: 10.1086/508213 – volume: 60 start-page: 548 year: 1986 ident: rf23_314 publication-title: J Virol doi: 10.1128/JVI.60.2.548-557.1986 |
| SSID | ssj0011805 ssj0004367 |
| Score | 2.266976 |
| Snippet | Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods. The... Background . Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. Methods . The... Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined. The HBoV VP2 gene,... Background. Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antlgenlc properties remain undefined. Methods. The... Human bocavirus (HBoV) is a newly identified human parvovirus for which seroepidemiology and antigenic properties remain undefined.BACKGROUNDHuman bocavirus... |
| SourceID | proquest pubmed pascalfrancis crossref oup jstor istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 41 |
| SubjectTerms | Adolescent Adult Amino Acid Sequence Animals Antibodies Antibodies, Viral - blood Antigens, Viral - immunology Antiserum Baculoviridae Baculovirus Biological and medical sciences Bocavirus - genetics Bocavirus - immunology Bocavirus - isolation & purification Capsid Proteins - chemistry Capsid Proteins - genetics Capsid Proteins - metabolism Cell Line Child Child, Preschool Children Enzyme linked immunosorbent assay Epidemiology Erythrovirus Fundamental and applied biological sciences. Psychology Human bocavirus Humans Immunoprecipitation Infant Infections Infectious diseases Medical sciences Microbiology Molecular Sequence Data Parvoviridae Infections - diagnosis Parvoviridae Infections - epidemiology Parvoviridae Infections - immunology Parvovirus Parvovirus B19, Human - immunology Parvovirus B19, Human - isolation & purification Rabbits Recombinant Proteins Seroepidemiologic Studies Specimens Virion - genetics Virion - immunology Virion - isolation & purification Viruses |
| Title | Seroepidemiology of Human Bocavirus Defined Using Recombinant Virus-Like Particles |
| URI | https://api.istex.fr/ark:/67375/HXZ-G5095SVW-7/fulltext.pdf https://www.jstor.org/stable/40253992 https://www.ncbi.nlm.nih.gov/pubmed/18491974 https://www.proquest.com/docview/19749420 https://www.proquest.com/docview/19752394 https://www.proquest.com/docview/71662037 |
| Volume | 198 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgEwgJIRgMOmDzA-OlCsrF8eVx7ELZuiGxdlR7ieLYEdVYO6UZYvx6juNcGkq5vURRcmJb-c6xz7HPBaFXSaIF2D2xI5iUDqHSdWAZJg6TaRxQL1VpkfHm-IT2huRwFI6qevdldEku3yTffxlX8j-owjPA1UTJ_gOydaPwAO4BX7gCwnD9K4xB0Ke6KfF60-zKv4Ul6us4u57BhJKCIqm61jfAWJuXsvB-6Z6Z905_fKFBjyz94-Z11SZqrEwsYd22oM3yVKc5B4o_2xCPZiP1SM-0HGctn-LdaV659Z42HsV72z7bAZv90gbcdA-z1k4Er71W5yMDPG4LHtWzq-ALbGTnSpvwqlx1bfbZhfncLY6XQs6preXTTph98iE6GPb70WB_NLiNVn2wFEwRi733R01obEBZlTDeDG2uvJRttaWPrBrR-la5plYxj_ev4hkITGornSw3RQqVZPAQPSixwTsWu0folp6soTu2uujNGrp7XPpNPEYff-YUPE1xwSm45hRccgouOAXPcQpuOAXXnPIEDQ_2B7s9p6ym4SRglOZOqPxQBSIQaWBy-oMqr6iMA0Kop0QgJVdCmNz-ingiVFIwsB2ZZEbf1kTCp-toZTKd6GcIcx2DtWMyTypGKFdSuyT1uKSB72ow6Dtou_qnUVKmmjcVT75EhcsDp5H99x20VdNd2eQqCxSvC0jq13F2YVwRWRj1RufRO1B3w9OzTxHroPUCs5qQgDJvki530AaAuLT5zRa2NZlvStB4FL7eqsCOYN41h2nxRIOkRR4Y4oL47m8pQh_mveUU0AP13QAG_9TyUTNMToTpYeOP_T9H9xpZfIFW8uxavwQ9OZebhST8AJ2nuig |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Seroepidemiology+of+Human+Bocavirus+Defined+Using+Recombinant+Virus-Like+Particles&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Kahn%2C+J+S&rft.au=Kesebir%2C+D&rft.au=Cotmore%2C+S+F&rft.au=D%27Abramo%2C+A+Jr&rft.date=2008-07-01&rft.issn=0022-1899&rft.volume=198&rft.issue=1&rft.spage=41&rft.epage=50&rft_id=info:doi/10.1086%2F588674&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |